Bardy Diagnostics CEO and leadership

Gust H. Bardy, M.D. serves as Chief Executive Officer and Chief Medical Officer providing strategic direction into all business functions and resources of the company and overseeing the clinical operations at Bardy Diagnostics. Dr. Bardy has been a cardiac electrophysiologist since 1983 with research interests in cardiac defibrillator technology, cardiac arrest, ablation, and atrial fibrillation from both a public health and a technical perspective. He has been a researcher and clinician in the field of sudden death and disabling cardiac rhythm disorders for 38 years with over 400 peer-reviewed publications. Dr. Bardy has also developed technological solutions to patient rhythm problems with over 240 U.S. patents issued, most of which have been incorporated in cardiac rhythm management technologies in use by many medical device companies. Most recently, Dr. Bardy’s previous company, Cameron Health, was successfully acquired by Boston Scientific in 2012 for its revolutionary Subcutaneous Implantable Defibrillator (S-ICD) product. In addition to serving Bardy Diagnostics, Dr. Bardy holds a faculty position as Clinical Professor of Medicine, Cardiology at the University of Washington and is the Director of the Seattle Institute for Cardiac Research. Dr. Bardy earned a BS in physics from Carnegie-Mellon University before completing his MD from Northwestern University Medical School. In addition, he completed his residency at Northwestern University and a fellowship in cardiology and electrophysiology at Duke University.

Ed Vertatschitsch is the Chief Operating Officer of Bardy Diagnostics. Prior to joining Bardy Diagnostics, Dr. Vertatschitsch was with Palm, Incorporated as the Manager, Hardware Development for seven years. His responsibilities included the launch of seven successful Palm Personal Digital Assistant (PDA) products, starting with Palm III series and ending with Tungsten W. These products contributed to the fastest adoption of computer technology in history - selling over one million units in the first 18 months following commercialization. Prior to Palm, Dr. Vertatschitsch was Chief Scientist at the Boeing Company and led the Phased Array Systems Organization including a technical team that developed military and commercial satellite communications phased array antennas. He had responsibility for signal processing algorithms for several fiber optic position sensors for Boeing's 'Fly-by-Light' initiatives early in his career at the Boeing Company.

Mark Querry serves as Chief Financial Officer, overseeing Bardy Diagnostics’ accounting, financial, and human resource functions. Mark has more than twenty years of experience in the medical device industry in a wide variety of roles. Most recently, Mark was Vice President and Chief Financial Officer for Calypso Medical Technologies, Inc., a pioneer in electromagnetic guidance technology used in conjunction with radiation therapy for prostate cancer and other solid tumors. While at Calypso, Mark helped to build out the team, raise capital, implement its reimbursement strategy, and develop leasing solutions for its customers. Prior to Calypso, Mark served as Director of Finance at EKOS Corporation, which developed a unique ultrasound-enabled drug delivery system for treating peripheral blood vessel occlusions. Mark also served as Finance Manager for Abbott Laboratories where he helped establish operating companies in several Eastern European countries. He began his career as an audit professional with Price Waterhouse. Mark earned a B.A. in English and Accounting from Hillsdale College.

Gust H. Bardy, M.D. serves as Chief Executive Officer and Chief Medical Officer providing strategic direction into all business functions and resources of the company and overseeing the clinical operations at Bardy Diagnostics. Dr. Bardy has been a cardiac electrophysiologist since 1983 with research interests in cardiac defibrillator technology, cardiac arrest, ablation, and atrial fibrillation from both a public health and a technical perspective. He has been a researcher and clinician in the field of sudden death and disabling cardiac rhythm disorders for 38 years with over 400 peer-reviewed publications. Dr. Bardy has also developed technological solutions to patient rhythm problems with over 240 U.S. patents issued, most of which have been incorporated in cardiac rhythm management technologies in use by many medical device companies. Most recently, Dr. Bardy’s previous company, Cameron Health, was successfully acquired by Boston Scientific in 2012 for its revolutionary Subcutaneous Implantable Defibrillator (S-ICD) product. In addition to serving Bardy Diagnostics, Dr. Bardy holds a faculty position as Clinical Professor of Medicine, Cardiology at the University of Washington and is the Director of the Seattle Institute for Cardiac Research. Dr. Bardy earned a BS in physics from Carnegie-Mellon University before completing his MD from Northwestern University Medical School. In addition, he completed his residency at Northwestern University and a fellowship in cardiology and electrophysiology at Duke University.

Mark Querry serves as Chief Financial Officer, overseeing Bardy Diagnostics’ accounting, financial, and human resource functions. Mark has more than twenty years of experience in the medical device industry in a wide variety of roles. Most recently, Mark was Vice President and Chief Financial Officer for Calypso Medical Technologies, Inc., a pioneer in electromagnetic guidance technology used in conjunction with radiation therapy for prostate cancer and other solid tumors. While at Calypso, Mark helped to build out the team, raise capital, implement its reimbursement strategy, and develop leasing solutions for its customers. Prior to Calypso, Mark served as Director of Finance at EKOS Corporation, which developed a unique ultrasound-enabled drug delivery system for treating peripheral blood vessel occlusions. Mark also served as Finance Manager for Abbott Laboratories where he helped establish operating companies in several Eastern European countries. He began his career as an audit professional with Price Waterhouse. Mark earned a B.A. in English and Accounting from Hillsdale College.